Considerations for postremission clinical decision-making. For patients with relatively low (<40%) risk of relapse, postremission consolidation may be deintensified to non-alloSCT (another cycle of chemotherapy or autologous stem cell transplantation). Several studies indicate this for favorable-risk patients and MRD-negative intermediate-risk patients.^19-21  AlloSCT has a stronger antileukemia effect but comes with more side effects and is therefore recommended for MRD-positive intermediate-risk patients and adverse risk patients, and some studies also showed benefit for FLT3/ITD-positive patients in first remission.^28,29  By MRD monitoring, early return of disease can be detected, which for non-alloSCT can be salvaged by alloSCT,²²  and for alloSCT, an increase in MRD levels can be an indication for further stimulating the antileukemia effect by donor lymphocyte infusions and a decrease of immunosuppression.^4,5  Created by BioRender.